WALTHAM, Mass. — Thermo Fisher Scientific Inc., a global leader in serving science, has opened its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in Philadelphia. This marks the company’s second ATxCC in the United States, following the opening of its site in Carlsbad, Calif. The two centers are part of Thermo Fisher’s growing nationwide network aimed at supporting innovation in cell and gene therapy (CGT) by providing advanced resources to biotech, biopharma, and translational researchers developing next-generation cell-based immunotherapies.
Advanced therapies have emerged as a transformative area in modern medicine, offering the possibility to treat or cure previously untreatable diseases. With increasing demand for these therapies, Thermo Fisher is investing in scalable, innovative solutions that help accelerate the development process. The new Philadelphia center reflects this commitment to equipping researchers and startups with the tools necessary to bring therapies from early-stage research to clinical readiness.
“Our new Advanced Therapies Collaboration Center in Philadelphia is designed to help innovators overcome critical hurdles in developing cell and gene therapies,” said Nicole Brockway, president of biosciences at Thermo Fisher Scientific. “This center will play a key role in supporting customers as they progress from the lab to the clinic and, most importantly, bring transformative therapies to patients faster.”
The center is located within BioLabs for Advanced Therapeutics Philadelphia, a recently expanded 53,000-square-foot biotech incubator in the heart of the city. It offers emerging startups and established biopharma organizations access to Thermo Fisher’s scientific expertise, advanced process development technologies, and collaborative resources. The facility includes integrated lab and coworking space, along with tailored guidance to help bring therapies to market.
“We’re proud to expand our network-wide partnership with Thermo Fisher Scientific through this unique offering. By embedding the ATxCC within the BioLabs community, we are creating a uniquely rich and accessible resource for founders and startup teams working on groundbreaking therapies in Philadelphia,” said Johannes Fruehauf, Ph.D., M.D., Founder and CEO of BioLabs. “It will offer game-changing access to high-end technologies not only for our BioLabs members but also to external high-potential biotechs from across the East Coast and internationally.”
